What is the name of the program launched in 2026 that helps Japanese healthcare startups expand into the United States?

The program is called the “J‑StarX US Healthcare Breakthrough” program, launched in 2026 as a partnership to assist Japanese medtech and digital health companies entering the U.S. market.

Which US‑based venture capital firm partnered with JETRO and the Mayo Clinic to create the 2026 J‑StarX US Healthcare Breakthrough program?

Kicker Ventures is the US‑based venture capital firm that partnered with JETRO and the Mayo Clinic to launch the 2026 J‑StarX US Healthcare Breakthrough program for Japanese healthcare startups.

What types of support does the J‑StarX US Healthcare Breakthrough program provide to Japanese medtech and digital health startups seeking entry into the US market?

The program offers strategic mentoring, regulatory guidance, and connections to the Mayo Clinic ecosystem for participating startups, helping them navigate the U.S. healthcare environment.

What are the two development tracks available in the J‑StarX US Healthcare Breakthrough program for participating companies, and which stages do they target?

The program includes an early‑stage track for nascent startups and a business‑development track for companies that are further along in commercialization, addressing both initial growth and scaling phases.

By what date must Japanese healthcare startups submit their applications to be considered for the 2026 J‑StarX US Healthcare Breakthrough program?

Applications must be submitted by June 1, 2026 in order to be eligible for participation in the J‑StarX US Healthcare Breakthrough program.

AI News NQ Analysis

Kicker Ventures Partners with Mayo Clinic Platform and JETRO to Support US Expansion of Japanese Healthcare Startups

NQ Score 85/100

AI Summary (NQ-processed)

Kicker Ventures 宣佈與 JETRO 及 Mayo Clinic 合作，推動 2026 年度 J-StarX 計畫，旨在支援日本醫療科技與數位健康新創公司開拓美國市場，提供專業策略輔導與臨床對接。

AI analysis data is not yet available.

Frequently Asked Questions

Q: What is the name of the program launched in 2026 that helps Japanese healthcare startups expand into the United States?: A: The program is called the “J‑StarX US Healthcare Breakthrough” program, launched in 2026 as a partnership to assist Japanese medtech and digital health companies entering the U.S. market.
Q: Which US‑based venture capital firm partnered with JETRO and the Mayo Clinic to create the 2026 J‑StarX US Healthcare Breakthrough program?: A: Kicker Ventures is the US‑based venture capital firm that partnered with JETRO and the Mayo Clinic to launch the 2026 J‑StarX US Healthcare Breakthrough program for Japanese healthcare startups.
Q: What types of support does the J‑StarX US Healthcare Breakthrough program provide to Japanese medtech and digital health startups seeking entry into the US market?: A: The program offers strategic mentoring, regulatory guidance, and connections to the Mayo Clinic ecosystem for participating startups, helping them navigate the U.S. healthcare environment.
Q: What are the two development tracks available in the J‑StarX US Healthcare Breakthrough program for participating companies, and which stages do they target?: A: The program includes an early‑stage track for nascent startups and a business‑development track for companies that are further along in commercialization, addressing both initial growth and scaling phases.
Q: By what date must Japanese healthcare startups submit their applications to be considered for the 2026 J‑StarX US Healthcare Breakthrough program?: A: Applications must be submitted by June 1, 2026 in order to be eligible for participation in the J‑StarX US Healthcare Breakthrough program.